<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04769479</url>
  </required_header>
  <id_info>
    <org_study_id>AG10-006</org_study_id>
    <nct_id>NCT04769479</nct_id>
  </id_info>
  <brief_title>A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Subjects</brief_title>
  <official_title>A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Tablet Formulations in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eidos Therapeutics, a BridgeBio company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eidos Therapeutics, a BridgeBio company</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single centre, open-label, 5-period study in healthy male and non-pregnant and&#xD;
      non-lactating healthy female subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is planned to enroll 14 subjects who will receive single oral doses of active IMP in a&#xD;
      sequential manner over 5 periods, with a minimum of 7days between dosing in each period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2021</start_date>
  <completion_date type="Anticipated">September 3, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 4, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Assessments: Cmax</measure>
    <time_frame>72 hours</time_frame>
    <description>Maximum Concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Assessments: AUC</measure>
    <time_frame>72 hours</time_frame>
    <description>Area under the plasma concentration-time curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Assessments: Tmax</measure>
    <time_frame>72 hours</time_frame>
    <description>Time to maximum concentration (Tmax)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Amyloidosis</condition>
  <arm_group>
    <arm_group_label>acoramidis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acoramidis</intervention_name>
    <description>acoramidis</description>
    <arm_group_label>acoramidis</arm_group_label>
    <other_name>AG10</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males or non-pregnant, non-lactating healthy females&#xD;
&#xD;
          -  Body mass index (BMI) of 18.0 to 32.0kg/mÂ² and a body weight&gt;50kg as measured at&#xD;
             screening&#xD;
&#xD;
          -  Must be willing and able to communicate and participate in the whole study&#xD;
&#xD;
          -  Must provide written informed consent&#xD;
&#xD;
          -  Must agree to adhere to the contraception requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have received any IMP formulation in a clinical research study within the&#xD;
             90 days prior to Period 1, Day 1&#xD;
&#xD;
          -  History of any drug or alcohol abuse in the past 2 years&#xD;
&#xD;
          -  Subjects with pregnant or lactating partners&#xD;
&#xD;
          -  Clinically significant abnormal clinical chemistry, haematology or urinalysis as&#xD;
             judged by the investigator. Subjects with Gilbert's Syndrome are allowed.&#xD;
&#xD;
          -  History of clinically significant cardiovascular, renal, hepatic, dermatological,&#xD;
             chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder,&#xD;
             as judged by the investigator&#xD;
&#xD;
          -  Presence or history of clinically significant allergy requiring treatment, as judged&#xD;
             by the investigator. Hay fever is allowed unless it is active&#xD;
&#xD;
          -  Subjects who are taking, or have taken, any prescribed or over-the-counter drug or&#xD;
             herbal remedies (other than up to 4g of paracetamol per day or HRT/hormonal&#xD;
             contraception) in the 14 days before first IMP administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Evans, MBChB, MRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark McGovern, RN, CCRN</last_name>
    <phone>+1 415-887-1471</phone>
    <email>medinfo@eidostx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Quotient Sciences</name>
      <address>
        <city>Ruddington</city>
        <state>Nottingham</state>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phillip Evans, MBChB, MRCS</last_name>
      <phone>44 0 115 974 9000</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 19, 2021</study_first_submitted>
  <study_first_submitted_qc>February 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2021</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

